Scion Life Sciences’ Post

In this intimate fireside chat, we will learn more about the Public Investment Corporation Early Stage Fund, cleverly structured to adress a number of challenges faced by startups. Cant wait!

So far in 2024, at least 25 VCs have collectively raised $17.3 bn to fuel the biopharma industry! Highlights include: 🧬 Flagship Pioneering leading with $3.6 bn 🧪 Arch Venture Partners securing $3 bn for Fund XIII. 💊 Forbion’s €2.1 bn ($2.3 bn) close, including a record-setting €1.2 bn for their late-stage fund, making it the largest-ever European biopharma fund. This influx of capital is a significant boost for AI/ML, digital health, and late-stage growth equity investments. 🚀 For more details, check out the BioCentury Inc. article by Stephen Hansen & Matthew Krebs. 🌐 #Biotech #VentureCapital #Biopharma #Investment #DigitalHealth #Growth

Did you know that Vespia offers a specialized KYB solution for Venture Capital firms? Verify investors 90% faster with a platform that allows you to screen entities in minutes and monitor them in real time. Vespia's KYB solution is tailored specifically for #VC firms, providing: ✅ Automated investor verification ✅ Access to robust global databases ✅ Real-time daily monitoring Check out the link in the comments for more details! #venturecapital #vc #kyb #verification #investment

Epoch 16: Gaining an Edge in Post-Pandemic Biotech 👉 $XBI down nearly 10% this week why not to worry 👉 Pandemic vs Post Pandemic investing 👉 Series A the new sweet spot for private deals? 👉 Round sizes trending up? 👉 More mega-rounds than ever... 👉 Where it is easiest to find lead investors 👉 Bcell depeltion musings 👉New Venture funds 👉Convertible note trends https://lnkd.in/dEkBy2bY

Q42023 Quartely Report for the PA MedTech VC Fund everyone:

Read the latest deals in tech, consumer & healthcare here: https://bit.ly/35DBrVG - Corporate venture deal value participation at high point - Return of speculative sentiment – meme stocks and crypto - Corporate profit strength; economic sentiment improving Private Placement/Financing Highlights: hexafarms, PolyAI, Codesphere, Manus M&A Highlights: Argos Wityu, StayinFront, GitKraken, OnKure Therapeutics This is a glimpse of our weekly digest of deals in the healthcare, technology & consumer sectors designed to provide a quick read-out of activity. We look forward to staying in touch with strategic and financing insight focused on the respective industry. #SWPTech #SWPHealthcare #SWPBonus #Inflation #Economy #venturefunding #venturecapital #privateequity #SWPconsumer #innovation #IP #startups #funding #vc #funding #outsourcing #investmentbanking

Our latest research looks at the fundraising stats by the top VC funds to date in 2024. And the outlook is positive: These VCs are sitting atop record amounts of dry powder, with capital on the sidelines waiting to be deployed. Despite sector headwinds, venture firms remain bullish and have raised $10.3 billion YTD, the second highest annual raise ever. Fund have shown a preference for fewer, larger deals despite having raised record amounts, hampering demand creation. Explore this research and more in the brand new 2024 Life Sciences Real Estate Perspective and Cluster Analysis >> https://lnkd.in/e62MspuS

EMV Capital passes £100m FUM milestone @EMVCapital #AIM #EMVC. EMV Capital (AIM:EMVC) PLC, the tech and life sciences venture capital group formerly known as NetScientific, passed a significant milestone in the first half as assets under management exceeded £100 million. The exact figure, £106.7 million, was up sharply from the £61.6 million posted this time last year. Within that overall number, there was a 12% increase in the fair value of its direct holdings, for third-party assets growth was a stellar 71%, while there was an addition of £24.1 million from the Martlet Capital portfolio as well as a £3.2 million increase in the managed portfolio. EMV's... http://ow.ly/RWYs105KorK

Our latest research looks at the fundraising stats by the top VC funds to date in 2024. And the outlook is positive: These VCs are sitting atop record amounts of dry powder, with capital on the sidelines waiting to be deployed. Despite sector headwinds, venture firms remain bullish and have raised $10.3 billion YTD, the second highest annual raise ever. Fund have shown a preference for fewer, larger deals despite having raised record amounts, hampering demand creation. Explore this research and more in the brand new 2024 Life Sciences Real Estate Perspective and Cluster Analysis >> https://lnkd.in/eU25DZsq

🎮 Venture Capital Deals in GameDev: Trends of 2023 and Beyond REVERA lawyers look back at 2023 and discuss key trends that shaped investment transactions in the gamedev industry. ✔ What transaction legal instruments are commonly used? ✔What risk-hedging mechanisms are gaining popularity? ✔How have compliance procedures developed over time? ✔What should we pay attention to and be ready for in 2024? Read more in our article 👉 https://lnkd.in/eRwj9PjB ⭐ 2024 stands to be an exciting year for the gamedev investment landscape. REVERA wishes you successful deals, prosperous projects, and investment victories in 2024!